PPCB News & Events

Propanc Biopharma announced an update on corporate progress as of December 31, 2025. Corporate and R&D Highlights: Accelerates IP Momentum: Files Four Provisional Patent Applications - Strengthening Global Protection for Breakthrough Proenzyme Formulations; Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal. "We are pleased with the advancements made with our R&D programs and in particular, our lead asset PRP which we are preparing for our world-first, Phase 1b, First-In-Human study in advanced cancer patients," said James Nathanielsz, CEO of Propanc. "We are executing several activities in preparation for this pivotal study, which we believe will become a future breakthrough treatment for metastatic cancer from solid tumors, especially fast spreading tumors with a poor patient prognosis where few treatment options exist. Activities include partnering with GMP manufacturing and bio-analytical contract organizations to produce the drug product and validate the pharmacokinetics method for the upcoming pivotal study. In the meantime, we continue to build the foundation for sustained success by extending our scientific research through partner universities, which enables further patentable discoveries including new therapeutic indications that could elevate proenzyme technology to future blockbuster status."

Propanc Biopharma highlighted the potential of its lead proenzyme therapy, PRP, as a novel approach that could compete with existing approved therapies for solid tumors, particularly in areas of high unmet need such as pancreatic cancer. Preclinical studies have demonstrated significant effects, including over 85% tumor growth inhibition in models and enhanced chemosensitivity, suggesting PRP could improve outcomes when used alongside or as an alternative to standard treatments. "We are excited about PRP's potential to transform cancer care by targeting the underlying mechanisms of metastasis with a mechanism that could offer meaningful advantages over existing therapies," said Mr James Nathanielsz, Propanc's Chief Executive Officer. "As we advance toward human trials, we remain committed to delivering hope to patients facing limited options for aggressive cancers from solid tumors."

Propanc Biopharma files to sell 7M shares of common stock for holders

Propanc Biopharma announced the filing of its fourth new provisional patent application in the past two months with IP Australia. This latest application focuses on formulations of the pancreatic proenzymes, trypsinogen and chymotrypsinogen. "Filing four provisional patent applications in such a short timeframe underscores our relentless drive to protect and expand our groundbreaking proenzyme technology," said Mr. James Nathanielsz, Propanc's Chief Executive Officer. "As these applications advance to national phase entry across major global markets, we expect to more than double our IP portfolio - from approximately 90 to over 200 patents - covering compositions, formulations, treatment methods, and new therapeutic indications.".